Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved- field radiotherapy: Interim results from the ongoing EORTC-LCG and GPMC phase III trial

Annals of Oncology

Volumn 8, Issue SUPPL. 1, 1997, Pages

  Raemaekers, J ^a   Burgers, M ^b   Henry Amar, M ^c   Pinna, A ^c   Mandard, A ^c   Monfardini, S ^d   Hagenbeek, A ^e   Breed, W ^f   Carde, P ^g   Vovk, M ^h   Van Hoof, A ⁱ   Thomas, J ^j   Noordijk, E ^k  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c CENTRE FRANÇOIS BACLESSE   (France)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f The Netherlands   (Netherlands)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h INSTITUTE OF ONCOLOGY   (Slovenia)

ⁱ General Hospital St Jan   (Belgium)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

chemotherapy; Hodgkin's disease (advanced); radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESPONSE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 8244252277     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/8.suppl_1.S111     Document Type: Conference Paper

References (11)

1. Fabian CJ, Mansfield CM, Dahlberg S et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease: A Southwest Oncology Group randomised study. Ann Intern Med 1994; 120: 903-12.
2. Loeffler M, Mauch P, MacLennan K et al. Workshop I of the Second International Symposium on Hodgkin's disease, Cologne: Review of prognostic factors. Ann Oncol 1992; 3 (Suppl 4): 63-7.
3. Pfreundschuh M, Lathan B, Loeffler M et al. Workshop III of the Second International Symposium on Hodgkin's disease, Cologne: Recommendations for future clinical trials. Ann Oncol 1992; 3 (Suppl 4): 101-5.
4. Carella AM, Prencipe E, Pungolino E et al. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy. Leuk Lymph 1995; 21: 63-70.
5. Lister TA, Crowther D. Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-6.
6. Klimo P, Connors JM. MOPP/ABV hybrid program: Combination chemotherapy based on introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 1985; 3: 1174-82.
7. Somers R, Carde P, Henry-Amar M et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994; 12: 279-87.
8. Loeffler M, Pfreundschuh M, Hasenclever D et al. Prognostic risk factors in advanced Hodgkin's lymphoma. Ann Hematol (formerly Blut) 1988; 56: 272-81.
9. Prosnitz LR, Farber LR, Kapp DS et al. Combined modality therapy for advanced Hodgkin's disease: Fifteen-year follow-up data. J Clin Oncol 1988; 6: 603-12.
10. Yahalom J, Ryu J, Straus DJ et al. Impact of adjuvant radiation on the patterns of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol 1991; 9: 2193-201.
11. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD. or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-84.